BrightSpring Health Services (NASDAQ:BTSG) outlined its growth strategy across pharmacy and provider services at the Bernstein healthcare services conference, emphasizing specialty pharmacy expansion, home health acquisitions, technology investments and opportunities to integrate services for complex patients.
Chief Financial Officer Jen Phipps described BrightSpring as a home- and community-based provider serving specialty and senior populations. The company divides its operations between pharmacy and provider services, with the premise that many patients require multiple services, including medications, primary care, home health, hospice and rehabilitation.
Growth Strategy Centers on Scale, M&A and Integration
Phipps said BrightSpring has completed about 80 acquisitions during the past decade and that almost all of those acquired businesses improved results after joining the company. The company sees acquisitions, operating initiatives, procurement capabilities and shared corporate infrastructure as contributors to growth.
BrightSpring also sees potential to deepen integration among its businesses. For example, Phipps said all of the company’s hospice patients receive medications through its home and community pharmacy operation. The company also sees referral opportunities between home health, hospice, primary care, pharmacy and rehabilitation services.
However, Phipps characterized the broader opportunity to capture cross-referral and payment-model synergies as being in the “early innings.” BrightSpring has established a dedicated team focused on senior-living opportunities across the enterprise, supplementing efforts already underway within individual business lines.
The company has also negotiated selected value-based arrangements. Phipps said certain large payers have approached BrightSpring because of its quality performance and requested that it take more patients. In response, the company reached differentiated case-rate arrangements based on quality and outcomes, she said.
BrightSpring expects to begin participating in its own accountable care organization in 2027, with 2028 expected to be a more meaningful year for the initiative, according to Phipps.
Specialty Pharmacy Remains a Major Growth Driver
BrightSpring’s pharmacy segment includes specialty pharmacy, home infusion and home and community pharmacy. Its specialty pharmacy business focuses primarily on oral and injectable medications for oncology and rare or orphan diseases, particularly medications distributed through limited distribution drug, or LDD, networks.
Phipps said the company competes for access to those drugs by emphasizing service levels, national coverage and sales relationships with oncology practices. She said BrightSpring’s time to first fill is approximately four days, or about half the industry average, while medication possession ratios are typically in the mid-90% range.
BrightSpring has launched roughly 16 to 20 LDDs annually in recent years and expects a similar number this year, Phipps said. Because newly launched medications can take several years to build adoption, the company believes those launches provide visibility into future growth.
“The drugs that we launch in 2026 typically will provide more meaningful growth in 2027 or 2028 or 2029,” Phipps said.
The company’s infusion operation primarily provides acute and chronic, non-oncology infusions in homes and clinics. Phipps said biosimilars are not currently a major factor in the business because BrightSpring is largely acute-focused, though the company sees opportunities to expand into chronic infusion categories over time.
Meanwhile, its home and community pharmacy serves settings including skilled nursing facilities, senior living communities, intellectual and developmental disability providers, PACE programs and hospice organizations. Phipps said the market grows at a low- to mid-single-digit rate, but BrightSpring is targeting faster-growing end markets and operational improvements.
Provider Segment Includes Home Health, Rehabilitation and Personal Care
On the provider side, BrightSpring operates home health care services, neurorehabilitation and personal care. The home health care subsegment includes home health, hospice and primary care.
Phipps said the provider business recorded more than 30% growth and nearly 20% year-over-year growth in the second quarter, while its home health care operations have historically grown at mid-teens rates or higher.
BrightSpring expanded its home health footprint through an acquisition completed at the end of December involving assets divested by Amedisys and LHC as part of their sale to United. Phipps said BrightSpring acquired most of the divested assets except those in Tennessee, where it had more overlap. The transaction effectively doubled the company’s home health component and has been performing ahead of its integration schedule, she said.
David Deuchler, BrightSpring’s head of investor relations, said home health remains a fragmented market with opportunities both to deepen density in current markets and expand into new geographies.
BrightSpring’s rehabilitation business is focused largely on traumatic brain injury and acquired brain injury care. Phipps described it as highly skilled, intensive neurorehabilitation that can involve outpatient, inpatient or in-home services. The company has also been building its Part B rehabilitation business for seniors, which it views as complementary to its home health, pharmacy and senior-living operations.
Technology Investment Targets Efficiency and Workforce Support
Phipps said BrightSpring has expanded its artificial intelligence initiatives over the past 13 to 14 months. The company hired a chief technology officer with prior experience at Google, CoreWeave and a payer, and has built an AI-focused team of nearly 30 people.
One project has focused on streamlining medication reconciliation for more than 200 consultant pharmacists in BrightSpring’s home and community pharmacy business. The technology is intended to consolidate information that may otherwise require pharmacists to review 15 to 20 screens and processes, freeing them for additional patient-facing or value-added work.
BrightSpring also cited workforce stability as a focus in its labor-intensive provider businesses. Phipps said turnover has improved in every quarter since the COVID period, while employee stability has increased. The company has invested in recruitment programs, career development, culture initiatives and human-resources capabilities to support retention and growth.
Looking ahead, Phipps said BrightSpring’s strategy remains centered on high-quality services and outcomes, which it believes can support above-market volume growth across its businesses.
About BrightSpring Health Services (NASDAQ:BTSG)
BrightSpring Health Services, Inc is a provider of home- and community-based health services and pharmacy services in the United States. The company supports individuals who require assistance with daily living, clinical care, rehabilitation, behavioral health services, or other long-term and post-acute care.
Its businesses include home health, hospice, personal care, residential and community living services, behavioral health programs, primary care, and rehabilitation. Through its PharMerica pharmacy business, BrightSpring provides institutional and specialty pharmacy services, including medication dispensing and related clinical support for long-term care facilities and other healthcare settings.
BrightSpring serves patients and clients across the United States through a network of local operations and care professionals.
